TuHURA Biosciences Reports Third Quarter 2026 Financial Results and Provides a Corporate Update

TAMPA, Fla., Nov. 13, 2026 // -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's third quarter ended Septe…